Visx Gains Panel Nod For Star S2 Hyperopia PRK Indication
This article was originally published in The Gray Sheet
Executive Summary
Labeling for Visx' Star S2 excimer laser for treatment of hyperopia (far-sightedness) with astigmatism using photorefractive keratectomy (PRK) should reflect the lack of data relating to refractive stability in the company's premarket approval application supplement, FDA's Ophthalmic Device Panel recommended at a May 11 meeting in Gaithersburg, Maryland.
You may also be interested in...
Alcon Eye Laser Hyperopia With Astigmatism Approval Provides Edge, For Now
FDA approval of Alcon Summit Autonomous' LADARVision device for laser-assisted in situ keratomileusis (Lasik) treatment of hyperopia with or without astigmatism, and for mixed astigmatism, gives the firm an exclusive market niche, if only temporarily.
Alcon Eye Laser Hyperopia With Astigmatism Approval Provides Edge, For Now
FDA approval of Alcon Summit Autonomous' LADARVision device for laser-assisted in situ keratomileusis (Lasik) treatment of hyperopia with or without astigmatism, and for mixed astigmatism, gives the firm an exclusive market niche, if only temporarily.
Summit Technology
CustomCornea wavefront system for guiding ablations during LADARVision ophthalmic laser vision correction procedures is granted expanded investigational device exemption to continue studies begun in October 1999. The multi-site trials include bilateral LASIK patients being treated for myopia, hyperopia, and astigmatism as well as ocular abnormalities such as irregular astigmatism and irregularities as a result of a prior refractive surgery